
Opinion|Videos|February 27, 2025
The Contemporary Treatment Landscape of mCRPC
Panelists discuss how the evolving treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) encompasses multiple therapeutic options including novel hormonal agents, chemotherapy, and targeted therapies while highlighting persistent challenges in treatment sequencing, drug resistance, and the need for improved biomarker-driven approaches to optimize patient outcomes.
Advertisement
Video Player is loading.
Episodes in this series

Now Playing
Video content above is prompted by the following:
- Can you briefly discuss the contemporary treatment landscape of mCRPC?
- What are the unmet needs for the treatment of mCRPC? Eg, access to agents.
- Treatment optimization to further delay disease progression and improve overall survival
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves subcutaneous pembrolizumab
2
FDA grants 510(k) clearance to new edition of Focal One robotic HIFU
3
Kim Nguyen Chi, MD, highlights patient-reported outcome data from AMPLITUDE
4
FDA greenlights pivotal trial of gene-editing therapy for PH1
5

















